Skip to main content
HOPA Highlights
The Impact of Racial Disparities in Cancer Care: Racism a Risk Factor for Poor Clinical Outcomes
Read More
HOPA Highlights
Eliminating Structural Racism in Oncology Pharmacy: Individual and Organizational Responsibility
Read More
HOPA Highlights
New Opportunities for Pharmacists in Clinical Trials and Drug Development After COVID-19
Read More
HOPA Highlights
Immunotherapy Continues to Transform the Treatment Landscape for Advanced Non–Small-Cell Lung Cancer
Read More
HOPA Highlights
Cancer Pain Management and the Opioid Conundrum: Optimizing Outcomes, Minimizing Risks
Read More
HOPA Highlights
Managing Thromboembolism in Patients with Cancer: Which Are the Preferred Anticoagulants?
Read More
FDA Updates
Lumakras First FDA-Approved Therapy for Advanced or Metastatic NSCLC with KRAS G12C Mutation
Read More
FDA Updates
Rybrevant First FDA-Approved Therapy for NSCLC with EGFR Exon 20 Insertion Mutations
Read More
FDA Updates
Zynlonta First FDA-Approved CD19-Directed Therapy for Large B-Cell Lymphoma
Read More
FDA Updates
Jemperli First FDA-Approved Immunotherapy for Advanced Endometrial Cancer with dMMR Biomarker
Read More
Page 87 of 196
Results 861 - 870 of 1954